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Purpose: Aurora-A, also known as STK15/BTAK, is a member of the protein serine/
threonine kinase family, and experimental studies have revealed that Aurora-A plays critical
roles in cell mitosis and in carcinogenesis. However, no clinical studies on Aurora-A expres-
sion in non-small-cell lung cancer (NSCLC) have been reported. Thus, the present study was
conducted to assess the clinical signiﬁcance of Aurora-A status.
Experimental Design: A total of 189 consecutive patients with resected pathologic (p-)stage
I-IIIA, NSCLC were retrospectively reviewed, and immunohistochemical staining was used to
detect Aurora-A expression.
Results: Aurora-A expression was negative in 31 patients (16.4%); among Aurora-A posi-
tive patients, 124 patients showed pure diffuse cytoplasmic Aurora-A expression and the other
34 patients showed perimembrane Aurora-A expression. Perimembrane Aurora-A tumors
showed the highest proliferative index (PI) (mean PIs for negative, diffuse cytoplasmic, and
perimembrane tumors: 49.2, 41.7, and 63.5, respectively; P < .001). Five-year survival rates of
Aurora-A negative, diffuse cytoplasmic, and perimembrane patients were 67.8%, 66.7%, and
47.6%, respectively, showing the poorest postoperative survival in perimembrane patients
(P = .033). Subset analyses revealed that perimembrane Aurora-A expression was a signiﬁ-
cant factor to predict a poor prognosis in squamous cell carcinoma patients, not in adeno-
carcinoma patients. A multivariate analysis conﬁrmed that perimembrane Aurora-A
expression was an independent and signiﬁcant factor to predict a poor prognosis.
Conclusions: Perimembrane Aurora-A status was a signiﬁcant factor to predict a poor
prognosis in correlation with enhanced proliferative activity in NSCLC.
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Primary lung cancer is the leading cause of cancer
deaths in most industrialized countries, and non-
small-cell lung cancer (NSCLC) accounts for 75–80%
of primary lung cancer. Surgery is the most effective
therapeutic modality for the cure, but the postoper-
ative prognosis remains poor.
1–3 To improve the
prognosis, establishment of biological markers other
than tumor-node-metastasis (TNM) factors that
determine prognosis and response to a particular
treatment is essential. Although many possible bio-
logical markers such as mutations of p53 and k-ras
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547genes have been reported, none of them has been
established as a marker in decision-making of the
treatment of NSCLC. In addition, most NSCLC
patients present with advanced stages and are
appropriate candidates for surgery. For inoperable
patients, chemotherapy with or without radiotherapy
may be given. Recently, tyrosine kinase inhibitors
targeting epidermal growth factor receptor (EGFR),
geﬁtinib and erlotinib, have been introduced into the
therapy of NSCLC, and experimental and clinical
studies have revealed that these agents induce dra-
matic antitumor effects for tumors with activating
mutations within the EGFR kinase domain.
4,5 Thus,
other molecular abnormalities in NSCLC should be
revealed in the development of useful prognostic
markers and in the development of effective molec-
ular targeting agents.
Aurora-A, also known as BTAK, STK15, Aurora-
2, ARKI, or AIKI, is a member of the serine/threo-
nine kinase family. As Aurora-A is involved in proper
centrosome functions and chromosome segregation
during normal cell mitosis,
6–8 its abnormalities such
as overexpression as well as gene ampliﬁcation may
contribute to development and progression of malig-
nant tumors.
9–11 In clinical studies, Aurora-A
abnormalities have been reported in a variety of
malignant tumor including glioma,
12 medullobras-
toma,
13 gastric cancer,
14 esophageal cancer,
15,16 pan-
creatic cancer,
17 ovarian cancer,
18 breast cancer,
19,20
bladder cancer,
21 and hepatocellular carcinoma.
22 In
all these clinical studies, Aurora-A gene was ampliﬁed
or Aurora-A expression was upregulated in tumor
tissues compared with normal tissues, which also
support experimental results suggesting that Aurora-
A abnormalities are involved in carcinogenesis. In
addition, many studies showed that Aurora-A
abnormalities were positively correlated with aggres-
sive tumor behavior such as poorly differentiated tu-
mor grade, invasion, and nodal metastasis,
15,16,19,20–22
but some studies showed no correlation
12,17 or an
inverse correlation.
18 Some studies also assessed a
prognostic signiﬁcance of Aurora-A status; most
studies showed that Aurora-A abnormalities were
correlated with a signiﬁcant poor prognosis,
13,16,21,22
but one study failed to show.
20 These results may
suggest that clinical signiﬁcant of Aurora-A status in
malignant tumors remains controversial. Moreover,
no clinical study on Aurora-A status in NSCLC has
been reported. Thus, we conducted a clinical study on
Aurora-A expression in resected NSCLC and assessed
its clinical signiﬁcance in correlation with other bio-
markers including proliferative activity.
PATIENTS AND METHODS
Patients
We retrospectively reviewed a total of 191 con-
secutive patients with pathologic (p)-stage I–IIIA
NSCLC who underwent complete tumor resection
and nodal dissection without any preoperative
therapy at the Department of Thoracic Surgery,
Kyoto University, between January 1, 1985 and
December 31, 1990. The p-stage was reevaluated
and determined according to the current tumor-
node-metastasis (TNM) classification as revised in
1997.
1 Histological type was also redetermined
according to the classiﬁcation by the World Health
Organization (WHO) as revised in 2004. Two pa-
tients who experienced operation-related death were
excluded from the study. Thus, a total of 189 pa-
tients were ﬁnally evaluated in the present study.
For all these patients, the inpatient medical records,
chest x-ray ﬁlms, whole-body computed tomography
(CT) ﬁlms, bone and gallium scanning data, and
records of surgery were reviewed without knowledge
of the results of immunohistochemical staining
(IHS) or the terminal deoxynucleotidyl transferase-
mediated dUTP-biotin nick end-labeling (TUNEL)
staining.
Details of postoperative adjuvant therapy were
described in previous studies.
23,24 In brief, cisplatin-
based chemotherapy, radiation, and oral adminis-
tration of tegafur (a ﬂuorouracil derivative drug)
were prescribed postoperatively for 47, 30, and 49
patients, respectively. Intraoperative therapy was not
performed on any patient.
The day of thoracotomy was considered the
starting day for counting postoperative survival
days. The median and mean follow-up periods
were 1697 and 1983 days, respectively (range, 50–
6381 days). This study has been approved by the
Ethics Committee of Faculty of Medicine, Kyoto
University.
Tissue Preparation
All tumor specimens were ﬁxed immediately in
10 vol% formalin, and then embedded in paraﬃn.
Serial 4-lm sections were prepared from each sample
and used for routine hematoxylin and eosin (HE)
staining, the TUNEL staining to detect apoptotic
cells, and IHS to determine Aurora-A expression
status, p53 status, intratumoral microvessel density
(IMVD), and proliferative index (PI).
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Aurora-A expression was evaluated using a stan-
dard streptavidin-biotinylated horseradish peroxidase
detection system. Dewaxed sections were incubated
overnight with a rabbit polyclonal antibody (KR051,
Transgenic Co. Ltd., Kumamoto, Japan; it had been
produced and its reliability had been conﬁrmed by
western blotting on a commercial basis) diluted at
1:100. Diaminobenzidine-tetrahydrochloride (0.03%)
containing 0.1% hydrogen peroxide was used as a
chromogen, and sections were counterstained with
hematoxylin. For negative control slides, rabbit
immunoglobulin G was used instead of the primary
antibody. Colon cancer sections that are known to
express Aurora-A were used as positive control slides.
Aurora-A expression on tumor cells was ﬁrst
classiﬁed into negative or positive expression; a slide
was judged to be Aurora-A positive expression,
regardless of the staining intensity. For slides with
positive Aurora-A expression, the staining pattern
was, then, classiﬁed as follows: diﬀuse cytoplasmic
staining (Fig. 1B), perimembrane staining (Fig. 1C).
Slides were evaluated by two pathologists (E.O. and
Y.T.) independently, without knowledge of any pa-
tient characteristic.
PI, IMVD, and p53 status were also determined
with IHS as described previously.
23,25 Brieﬂy, an anti-
PCNA monoclonal antibody (PC-10, mouse immu-
nogloblin G [IgG] 2a, kappa; DAKO Japan, Kyoto,
Japan) diluted at 1:50 was used as the primary anti-
body to determine PI;
23 PI was deﬁned as the per-
centage of PCNA-positive staining tumor cells.
IMVD was determined with an anti-CD34 mono-
clonal antibody QBEnd10 (mouse IgG1, kappa;
DAKO Japan) diluted at 1:50; the 10 most vascular
areas within a section were selected for evaluation of
angiogenesis, and the average counts of CD34-posi-
tive vessels were recorded as IMVD in each case.
25
An antihuman p53 monoclonal antibody DO-7
(mouse IgG2b, kappa, 250 lg/mL, DAKO Japan)
was used to determine p53 status. When the per-
centage of positive-staining cells exceeded 5%, the
slide was judged to exhibit aberrant expression of
p53.
23
Detection of Apoptosis
The TUNEL staining was performed using the In
Situ Death Detection Kit, POD (Boehringer Man-
heim, Manheim, Germany) following the manufac-
tures protocol as described previously.
23 The
speciﬁcity of the TUNEL staining of apoptotic cells
was conﬁrmed by making the negative and the posi-
tive control slides at every staining. As negative
control slides, sections incubated with the TUNEL
reaction mixture without TdT were used. Sections
treated with DNase I (Stratagene, La Jolla, CA) be-
fore the TUNEL reaction were used as positive
control slides. Apoptotic cells were determined with
careful observation of TUNEL-staining sections and
serial HE-staining sections, and TUNEL-positive
FIG. 1. Aurora-A expression in non-small-cell carcinoma
(NSCLC) as detected with imuunohistochemical staining. A Neg-
ative staining. B diffuse cytoplasmic staining. C Peri-membrane
staining.
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features of necrosis in HE-staining sections, were not
considered to be apoptotic cells. In each case, a total
of 10,000 tumor cells, consisting of 1000 tumor cells
each in 10 different ﬁelds, were evaluated at high
magniﬁcation (400·). The apoptotic index (AI) was
deﬁned as the number of apoptotic cells per 1000
tumor cells.
Statistical Analysis
Counts were compared by the chi-square test.
Continuous data were compared using the t test if the
distribution of the samples was normal, or using the
Mann-Whitney U test if the sample distribution was
asymmetrical. The postoperative survival rate was
analyzed by the Kaplan-Meier method, and differ-
ences in the survival rates were assessed by the log-
rank test. Death from any cause was included in
calculation of postoperative survival. Multivariate
analysis of the prognostic factors was performed
using Coxs proportional hazard model. Differences
were considered signiﬁcant when the P value was less
than .05. All statistical manipulations were per-
formed using the SPSS ver.10 for the Windows soft-
ware system (SPSS Inc., Chicago, IL).
RESULTS
Expression of Aurora-A in NSCLC
Expression of Aurora-A was not observed in nor-
mal adjacent lung tissues in any patient. Expression
of Aurora-A in tumor cells was negative in 31 pa-
tients (16.4%) and positive in the other158 patients.
Among Aurora-A positive patients, 124 patients
showed diﬀuse cytoplasmic staining, 6 patients
showed pure perimembrane staining, and 28 patients
showed both diﬀuse cytoplasmic staining and pe-
rimembrane staining (mixed staining). Because the
number of patients showing pure perimembrane
staining was very small (n = 6), both patients with
pure perimembrane staining and patients with mixed
staining were classiﬁed into perimembrane patients.
Thus, there were 31 negative patients (16.4%), 124
diffuse cytoplasmic patients (65.6%), and 34 perim-
embrane patients (18.0%) (Table 1).
The incidence of perimembrane staining was sig-
niﬁcantly higher in higher p-stages; perimembrane
staining was seen in only 11.5% (12 of 104) of p-stage
I patients, but seen in as high as 25.8% (22 of 85) of
p-stage II–IIIA patients (Table 1). There was no
signiﬁcant correlation between Aurora-A expression
status and any other patients characteristic (Table 1).
The mean PI for perimembrane Aurora-A expres-
sion patients high tumor was signiﬁcantly higher than
that for Aurora-A negative or that for diﬀuse cyto-
plasmic Aurora-A expression patients (PIs: 63.5,
49.2, and 41.7, respectively; P < .001) (Table 2).
There was no signiﬁcant difference in the mean
IMVD or in the mean AI according to the status of
Aurora-A expression; there was no signiﬁcant corre-
lation between Aurora-A expression status and p53
status (Table 2).
Expression of Aurora-A and Postoperative Survival
For all 189 patients, 5-year survival rates of Aur-
ora-A negative patients, diﬀuse cytoplasmic Aurora-
A patients, and perimembrane Aurora-A patients
were 67.8%, 66.7%, and 47.6%, respectively; perim-
embrane Aurora-A patients showed the poorest
postoperative survival (P = .033) (Table 3 and
Fig. 2).
Subset analyses revealed that perimembrane Aur-
ora-A expression was a signiﬁcant factor to predict a
poor prognosis in squamous cell carcinoma patients,
not in adenocarcinoma patients (P = .007 and
P = .894, respectively) (Table 3).
A multivariate analysis of prognosis factors using a
Cox proportional hazard model conﬁrmed that pe-
rimembrane Aurora-A expression was an indepen-
dent and signiﬁcant factor to predict a poor
prognosis in NSCLC (Table 4).
DISCUSSION
The present study is the ﬁrst clinical study on
Aurora-A expression in NSCLC and has revealed the
clinical signiﬁcance as follows: (1) positive Aurora-A
expression is exclusively observed in tumor cells, not
in normal cells; (2) there are two Aurora-A expres-
sion patterns, diﬀuse cytoplasmic staining and pe-
rimembrane staining; (3) perimembrane staining is
signiﬁcantly correlated to higher p-stage and higher
proliferative activity; and (4) perimembrane staining
is a signiﬁcant and independent factor to predict a
poor prognosis, especially in squamous cell carci-
noma patients. As mentioned in the introduction
section, previous experimental and clinical studies
have demonstrated that Aurora-A is overexpressed
and upregulated in tumor cells and/or tissues,
8–20,22,26
which is also true in NSCLC as demonstrated in the
present study. The centrosomes play important roles
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lishing bipolar spindles during mitosis and by ensur-
ing equal segregation of replicated chromosome into
two daughter cells.
27 Aurora-A is involved in normal
centrosome functions, and its abnormalities such as
gene ampliﬁcation and overexpression may lead to
TABLE 2. Correlation between Aurora expression and other biomarkers
Aurora expression
P value Negative
Positive
Diffuse cytoplasmic Perimembrane
Intratumoral microvessel density (IMVD)
* 191.2 ± 16.3 174.7 ± 8.9 167.6 ± 14.6 .584
Proliferative index (PI) (%) 49.2 ± 4.8 41.7 ± 2.5 63.5 ± 3.8 <.001
Apoptotic index (AI) (/1000 tumor cells) 13.5 ± 3.2 20.5 ± 2.0 15.9 ± 2.5 .154
p53-status: Aberrant expression (+) 12/31 (38.7%) 55/124 (44.4%) 15/34 (44.1%) .848
Values were shown as the mean ± standard error (SE).
* Evaluated with an anti-CD34 antibody.
TABLE 3. Aurora expression and postoperative survival in non-small-cell lung cancer (NSCLC) patients
5-year survival rate (%)
P value
AURORA expression
Negative
Positive
Diffuse cytoplasmic Perimembrane
All patients 67.8% 66.7% 47.6% .033
Subset analysis, histologic type
Squamous cell (Sq) 75.0% 74.2% 34.5% .007
Adeno (Ad) 64.2% 60.8% 62.5% .894
Pathologic (p-)stage
I 91.7% 72.9% 58.3% .098
II 75.0% 68.6% 57.1% .579
IIIA 50.4% 50.9% 28.9% .088
TABLE 1. Characteristics of patients and Aurora expression
No. of patients (%)
MAGE-D4 expression
P value Negative
Positive
Diffuse cytoplasmic Perimembrane
All patients 189 (100) 31 (16.4%) 124 (65.6%) 34 (18.0%)
Age (mean ± SD) 62.4 ± 9.6 60.5 ± 10.2 62.3 ± 9.2 64.3 ± 9.1 0.256
Sex .137
Male 133 (70.4) 26 (19.5%) 86 (64.7%) 21 (15.8%)
Female 56 (29.6) 5 (8.9%) 38 (67.9%) 13 (23.2%)
Performance status (PS) .353
0 164 (86.8) 28 (17.1%) 109 (66.5%) 27 (16.5%)
1–2 25 (13.2) 3 (12.0%) 15 (60.0%) 7 (28.0%)
Histologic type .302 (Sq vs Ad)
Squamous cell (Sq) 64 (33.9) 8 (12.5%) 41 (64.1%) 15 (23.4%)
Adeno (Ad) 108 (57.1) 19 (17.6%) 73 (67.6%) 16 (14.8%)
Large cell (La) 10 (5.3) 4 (40.0%) 4 (40.0%) 2 (20.0%)
Others 7 (3.7) 0 (0.0%) 5 (85.7%) 1 (14.3%)
Tumor differentiation
* .393
Well 68 (37.4) 9 (13.2%) 49 (72.1%) 10 (14.7%)
Moderately 67 (36.8) 13 (19.4%) 43 (64.2%) 11 (16.4%)
Poorly 47 (25.8) 9 (19.1%) 26 (55.3%) 12 (25.5%)
Pathologic (p-) stage .007 (for all p-stage)
I 104 (55.0) 12 (11.5%) 80 (76.9%) 12 (11.5%)
II 22 (11.6) 4 (18.2%) 11 (50.0%) 7 (31.8%)
IIIA 63 (33.3) 15 (23.8%) 33 (52.4%) 15 (23.8%)
* Other histologic types were excluded in the analyses.
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bility, and carcinogenesis.
26 Aurora-A gene ampliﬁ-
cation usually contributes to overexpression of
Aurora-A gene and Aurora-A protein, but also
common is overexpression without gene ampliﬁca-
tion.
22 These results may suggest that Aurora-A
expression is regulated not only by gene ampliﬁcation
but also by other mechanisms.
22 In the present study,
only Aurora-A protein expression was assessed
immunohistochemically, and comparative study of
overexpression and ampliﬁcation should be con-
ducted in future.
In previous clinical studies on Aurora-A expression
assessed with IHS, Aurora-A expression was classi-
ﬁed simply into negative or positive, and its clinical
signiﬁcance was examined.
13,15–18,20 Some studies
showed a signiﬁcantly positive correlation between
Aurora-A overexpression and aggressive tumor
behavior such as poor differentiation and nodal
metastasis,
15,16,20 but others showed no
17 or an in-
verse correlation.
18 In addition, among three studies
where prognostic signiﬁcance of Aurora-A overex-
pression was assessed, two studies showed a signiﬁ-
cantly poor prognosis in patients with Aurora-A
overexpression
13,16 and one failed to show.
20 These
conﬂicting results on clinical signiﬁcance of Aurora-A
expression status might be partly due to the evalua-
tion system. In fact, there was no difference in the
proliferative activity as represented as PI or in the
prognosis between negative Aurora-A tumors and
diffuse cytoplasmic Aurora-A tumors in the present
study (Tables 2 and 3); when perimembrane Aurora-
A expression was separated and analyzed, tumors
with perimembrane Aurora-A expression showed an
aggressive tumor phenotype correlated with a higher
PI and a poor prognosis. The biochemical implica-
tion of perimembrane Aurora-A expression is un-
known, staining patterns should be taken into
consideration in evaluation of Aurora-A expression
status in clinical samples.
Another reason for conﬂicting results of clinical
signiﬁcance of Aurora-A expression status might be
diﬀerence in the histologic type. Two clinical studies
on esophageal squamous cell carcinoma showed that
Aurora-A overexpression was signiﬁcantly correlated
with aggressive tumor behavior.
15,16 In contrast, two
clinical studies on adenocarcinoma, one on pancre-
atic cancer
17 and one on breast cancer,
20 failed to
show a signiﬁcant correlation between Aurora-A
status and tumor differentiation or prognosis. In fact,
a subset analysis according to histologic types in the
present study showed that perimembrane Aurora-A
expression was a signiﬁcant factor to predict a poor
prognosis in lung squamous cell carcinoma, but not
in lung adenocarcinoma (Table 3). These results may
suggest that clinical impact of Aurora-A expression
status is enhanced in squamous cell carcinoma and
reduced in adenocarcinoma. Further clinical studies
on a variety of malignant tumors will give some an-
swers to the issue.
We analyzed correlations between Aurora-A status
and other biomarkers such as proliferative activity
and p53 status. There has been no clinical study
where Aurora-A status is assessed in correlation with
proliferative activity. Considering experimental re-
sults that Aurora-A is a centrosome-associated kinase
that contributes to regulation of cell mitosis,
8,26
Aurora-A expression status may be correlated with
proliferative activity in clinical samples as shown in
the present study (Table 2). However, it remains
unknown why a speciﬁc Aurora-A expression pat-
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FIG. 2. Survival curves of patients who underwent complete
resection for pathologic (p-) stage I–IIIA non-small-cell lung can-
cer. Comparison according to Aurora-A expression status.
TABLE 4 Multivariate analysis of prognostic factors (Coxs proportional hazard model)
Factors Beta P value Hazard ratio (95% conﬁdence interval)
Gender (male/female) )0.539 .096 0.583 (0.309–1.101)
Age 0.006 .714 1.006 (0.977–1.035)
Performance status (0/1/2) 0.183 .571 1.201 (0.637–2.264)
Histologic type (Nonadenocarcinoma/adenocarcinoma) )0.050 .162 0.951 (0.887–1.020)
Pathologic stage (I/II/IIIa) 0.551 .001 1.734 (1.311–2.295)
Perimembrane Aurora expression (No/Yes) )0.362 .032 0.343 (0.169–0.699)
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higher proliferative activity. Experimental studies
have also suggested an interaction between Aurora-A
and p53,
28–30 suggesting that the p53 inhibit onco-
genic activity of Aurora-A
28 and that Aurora-A,
especially when overexpressed, inactivate tumor-
suppressor activity of p53.
29,30 One clinical study also
documented that Aurora-A overexpression was sig-
niﬁcantly correlated with p53 mutation in hepato-
cellular carcinoma.
22 These results strongly suggest
that Aurora-A in concert with p53 contributes to the
development and progression of malignant tumors.
In the present study, we failed to show a signiﬁcant
correlation between Aurora-A expression status and
p53 status as assessed with IHS. In a future study, p53
gene mutation status in correlation with Aurora-A
expression should be examined.
More recently, increasing studies on Aurora-A gene
polymorphisms and risk of malignant tumors have
been reported.
31–36 Two common single nucleotide
polymorphisms in the coding regions are 91T->A
transversion and 169G->A transversion, which result
in phenylalanine/isoleucine substitution at amino acid
31 (F31I) and valine/isoleucine substitution at amino
acid 57 (V57I), respectively. Several studies have
shown such polymorphisms are associated with in-
creased risk of occurrence of a variety of malignant
tumors including esophageal,
31,35 ovarian,
32 and
breast
33,34 cancers. In future, correlation between
Aurora-A polymorphism and risk of development of
primary lung cancer should be investigated. In con-
clusion, Aurora-A expression status was a signiﬁcant
prognostic factor in correlation with proliferative
activity in NSCLC. To conﬁrm the clinical signiﬁ-
cance, future prospective studies should be conducted.
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